Carfilzomib, venetoclax and dexamethasone for relapsed/refractory multiple myeloma.

Encouragingly, a phase 1 clinical trial evaluating venetoclax with bortezomib and dexamethasone in RRMM patients resulted in a promising ORR of 67% that did not differ between t(11;14)-positive and negative patients (Moreau I et al. i , [8]). These results prompted us to evaluate KVenD in 14 heavily pretreated RRMM patients, including t(11;14)-negative patients, in three departments of haematology. Regarding efficacy, ORR on KVenD among all patients was 5/14 (35-7%), with all responding patients in VGPR or better (Fig). [Extracted from the article]